Professional Documents
Culture Documents
Dermatologica Sinica
journal homepage: http://www.derm-sinica.com
REVIEW ARTICLE
Drug Hypersensitivity Clinical and Research Center, Department of Dermatology, Chang Gung Memorial Hospital, Taipei, Keelung, Taiwan
School of Medicine, Chang Gung University, Taoyuan, Taipei and Linkou Branches, Taiwan
a r t i c l e i n f o
a b s t r a c t
Article history:
Received: Aug 22, 2013
Revised: Sep 24, 2013
Accepted: Sep 24, 2013
Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) are rare but life-threatening severe
cutaneous adverse reactions (SCARs), which are mainly induced by a variety of drugs. Once considered to
be unpredictable, signicant progress has been achieved in understanding the pathological mechanisms
underlying such reactions. Recent studies suggested that SJS/TEN is a specic immune reaction where
human leukocyte antigen (HLA) alleles specic for certain drugs in dened populations are involved in
the activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Upon the activation, various
cytotoxic and immunological signals, including but not limited to Fas/Fas ligand, perforin/granzyme B,
and granulysin are launched to mediate the disseminated keratinocyte death in SJS/TEN. This review
provides an update on the pathobiology of SJS/TEN in both the genomic and immunologic perspectives.
The knowledge gained from these cutting-edge studies will form the basis for better prevention and
management of SJS/TEN.
Copyright 2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.
Keywords:
drug hypersensitivity
human leukocyte antigens
Stevens-Johnson syndrome
toxic epidermal necrolysis
Introduction
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are considered a spectrum of rare but potentially fatal cutaneous diseases, differing only in their extent of skin detachment
[with the degree of epidermal detachment less than 10% of body
surface area (BSA) being classied as SJS, greater than 30% as TEN,
and 10e30% as SJS/TEN overlap] (Figure 1).1 Histopathology typically shows widespread keratinocyte apoptosis and full-thickness
epidermal necrosis and detachment with a sparse dermal monocytic (predominantly T cell) inltrate.2 Without immediate medical
intervention, uncontrolled separation of the epidermis can lead to
large denuded areas that cause extreme pain, massive loss of uid
and protein, bleeding, evaporative heat loss with subsequent hypothermia, and infection.3
Although microbial infections have occasionally been reported
as the causes of SJS/TEN, this devastating disease is mainly triggered by drug exposure.1,4e6 To date, more than 100 drugs have
been associated with SJS and TEN,1 among which aromatic anticonvulsants, sulfonamide antibiotics, allopurinol, oxicam nonsteroidal anti-inammatory drugs, and nevirapine exhibit a high
* Corresponding author. Drug Hypersensitivity Clinical and Research Center,
Department of Dermatology, Chang Gung Memorial Hospital, No. 5, Fusing St.,
Gueishan Township, Taoyuan County 333, Taiwan.
E-mail address: chung1@cgmh.org.tw (W.-H. Chung).
1027-8117/$ e see front matter Copyright 2013, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights reserved.
http://dx.doi.org/10.1016/j.dsi.2013.09.002
176
Figure 1 Histological analysis of a toxic epidermal necrosis (TEN) skin section with
prominent keratinocyte death and separation at the dermoepidermal junction (black
arrows).
MHC ligand that is loaded onto the MHC and trafcked to the cell
surface, where it activates antigen-specic T lymphocytes.25,26 In
some cases where drug hypersensitivity takes place rapidly, the
immunogenic complexes produced by drug presentation are unlikely to depend on antigen processing or cellular metabolism. A
second concept, the pei or pharmacological interaction with immune receptors model, therefore, is proposed, according to which
a noncovalent, labile interaction of the drug with the MHC receptor at the cell surface is involved in MHC-dependent T cell
stimulation by various drugs.27 Neither cellular metabolism nor
antigen processing is required in such an interaction. Recently, we
identied shared and restricted T cell receptor (TCR) usage in
carbamazepine (CBZ)-induced SJS/TEN patients28 and also
demonstrated that the endogenous peptide-loaded HLA-B*1502
molecule presented CBZ to CTLs without the involvement of
intracellular drug metabolism or antigen processing.29 These
ndings favor a role of the pei model in the pathogenesis of CBZinduced SJS/TEN.
Another concept, the altered repertoire model, has recently
been proposed. In this model, it is postulated that drugs or drug
metabolites can bind noncovalently within the pocket of the peptide binding groove of certain MHC molecules with exquisite
specicity, allowing a new repertoire of endogenous self-peptides
to be bound and presented. Various studies of abacavir-mediated
drug hypersensitivity have documented that the binding of abacavir to the antigen-binding cleft of HLA-B*5701 sterically hindered
the binding of the original repertoire of peptides, thereby
prompting the binding of a new repertoire of peptides bearing
immunogenic neoepitopes.30e32 In addition, a similar process is
also observed in the interaction of CBZ with HLA-B*1502 in SJS/TEN
cases.30 However, this model is insufcient to explain the clinical
observation that there are approximately 7% of tolerant CBZ users
who carry the predisposing allele, HLA-B*1502, while the drug
essentially alters the peptide repertoire in every carrier of the risk
allele as proposed. Moreover, about 8% of Han Chinese are carriers
of HLA-B*1502, but the prevalence of CBZ-induced SJS/TEN in this
population is much lower (< 0.1% of new users). This suggests that
additional determinants are implicated in the development of CBZmediated SJS/TEN.
Figure 2 The proposed model of keratinocyte apoptosis in Stevens-Johnson syndrome (SJS)/toxic epidermal necrosis (TEN). As illustrated, the immune response is triggered by the
human leukocyte antigen (HLA; e.g. HLA-B*1502)-dependent presentation of an antigen (an interaction of an endogenous self-peptide with a causative drug/metabolite) to specic
T cell receptors (TCRs) on the CD8 cytotoxic T cells. Upon this recognition, cytotoxic T cells produce cytokines/chemokines as well as various cytotoxic proteins to induce extensive
keratinocyte apoptosis.
HLA allele
Ethnic population
Refs
Allopurinol
B*5801
40e44
Carbamazepine
B*1502
B*1511
B*5901
A*3101
Korean, Japanese
European
Han Chinese
Han Chinese, Thai
European
50
Lamotrigine
Methazolamide
Oxicam
Oxcarbazepine
Phenytoin
Sulfamethoxazole
B*1502, B*38
B*5801, A*6801
Cw*0718
DQB1*0609
DRB1*1301
B*5901, CW*0102
B*73, A*2, B*12
B*1502
B*1502
B*38
177
34e37
47
69
46,48,70
44,49,71
44,71
49
36,49
44
178
Figure 3 Geographic distribution of drugehuman leukocyte antigen (HLA) association in Stevens-Johnson syndrome (SJS)/toxic epidermal necrosis (TEN). This illustration depicts
the ethnic specicity in the association of HLA with drug-induced SJS/TEN. ALL allopurinol; CBZ carbamazepine; LMT lamotrigine; MTZ methazolamide; NVP nevirapine;
OXC oxcarbazepine; PHT phenytoin; SMX sulfamethoxazole.
epidermal necrolysis, offer us a solid foundation for disease prevention and early diagnosis, as well as providing the potential
therapeutic target for the treatment of SJS/TEN. The translation of
HLA-B*1502 and CBZ-induced SJS/TEN from discovery to a
guideline-based test used routinely in Taiwan is a notable example
(Table 2). Although the incidence has improved with the successful
179
24. Zakrzewski JL, Lentini G, Such U, et al. Toxic epidermal necrolysis: differential
diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell
transplant recipient. Bone Marrow Transplant 2002;30:331e3.
25. Pohl LR, Satoh H, Christ DD, et al. The immunologic and metabolic basis of drug
hypersensitivities. Annu Rev Pharmacol Toxicol 1988;28:367e87.
26. Padovan E, Bauer T, Tongio MM, et al. Penicilloyl peptides are recognized as T cell
antigenic determinants in penicillin allergy. Eur J Immunol 1997;27:1303e7.
27. Pichler WJ. Pharmacological interaction of drugs with antigen-specic immune
receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2:301e5.
28. Ko TM, Chung WH, Wei CY, et al. Shared and restricted T-cell receptor use is
crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin
Immunol 2011;128:1266e76 e11.
29. Wei CY, Chung WH, Huang HW, et al. Direct interaction between HLA-B and
carbamazepine activates T cells in patients with Stevens-Johnson syndrome.
J Allergy Clin Immunol 2012;129:1562e9 e5.
30. Illing PT, Vivian JP, Dudek NL, et al. Immune self-reactivity triggered by drugmodied HLA-peptide repertoire. Nature 2012;486:554e8.
31. Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A
2012;109:9959e64.
32. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides
into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. Aids 2012;26:F21e9.
33. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal
necrolysis. Arch Dermatol 1987;123:1171e3.
34. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for StevensJohnson syndrome. Nature 2004;428:486.
35. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and
antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia
2007;48:1015e8.
36. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin
induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in
Thai population. Epilepsia 2008;49:2087e91.
37. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and
carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J
Dermatol Venereol Leprol 2009;75:579e82.
38. Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous
adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011;97:
190e7.
39. Alrevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813e8.
40. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic
epidermal necrolysis. Pharmacogenomics 2008;9:1617e22.
41. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for
severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S
A 2005;102:4134e9.
42. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and
toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics
2009;19:704e9.
43. Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I
alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics
2011;21:303e7.
44. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in StevensJohnson syndrome and toxic epidermal necrolysis related to ve high-risk
drugs. Pharmacogenet Genomics 2008;18:99e107.
45. Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced
cutaneous adverse drug reactions in Japanese population. Hum Mol Genet
2011;20:1034e41.
46. McCormack M, Alrevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:
1134e43.
47. Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for
carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010;51:2461e5.
48. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepineinduced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:
297e306.
49. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepilepticdrug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in
Han Chinese. Pharmacogenomics 2010;11:349e56.
50. Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with
methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010;11:879e84.
51. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by
blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:
490e3.
52. Viard-Leveugle I, Bullani RR, Meda P, et al. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. J Biol Chem 2003;278:16183e8.
53. Paquet P, Pierard GE. Keratinocyte injury in drug-induced toxic epidermal
necrolysis: simultaneous but distinct topographic expression of CD95R and
calprotectin. Int J Mol Med 2002;10:145e7.
180
64. Wang CW, Chung WH, Cheng YF, et al. A new nucleic acid-based agent inhibits
cytotoxic T lymphocyte-mediated immune disorders. J Allergy Clin Immunol
2013;132:713e22.
65. Paquet P, Paquet F, Al Saleh W, et al. Immunoregulatory effector cells in druginduced toxic epidermal necrolysis. Am J Dermatopathol 2000;22:413e7.
66. Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis
factor alpha, and interleukin 6 levels in blister uid of toxic epidermal necrolysis. J Am Acad Dermatol 2002;47:58e62.
67. Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol
2004;114:335e40.
68. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and
Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006;155:
722e8.
69. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients
with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010;51:
297e300.
70. Niihara H, Kakamu T, Fujita Y, et al. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepineinduced lymphocyte proliferation in a Japanese population. J Dermatol
2012;39:594e601.
71. Kazeem GR, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe
cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet
Genomics 2009;19:661e5.